Cover Image

Advanced therapy medicinal products (ATMPs) – An analysis of the global regulatory status

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Allan Cramer, Freja Karuna Hemmingsen Sørup, Marie Lund, Tonny Studsgaard Petersen, Kristian Karstoft
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	British Journal of Clinical Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report
by: Mariam Nersesjan, et al.
Published: (2024)

The clinical toxicity of advanced therapy medicinal products
by: Fraser J. H. Henderson, et al.
Published: (2025)

Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients
by: Gary M. Noonan, et al.
Published: (2024)

Precision medicine in paediatrics: Progress and priorities
by: Nicola Husain, et al.
Published: (2026)

Clinical pharmacology in adolescent transgender medicine
by: Lauren R. Cirrincione, et al.
Published: (2024)

Section 19A in practice: Assessing the provision of overseas‐registered medicines to mitigate the impact of medicine shortages in Australia
by: Jack Janetzki, et al.
Published: (2025)

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
by: Olivia C. Lewis, et al.
Published: (2026)

Innovations in pharmacovigilance studies of medicines in older people
by: Lisa M. Kalisch Ellett, et al.
Published: (2024)

Optimizing real‐world evidence studies for regulatory decision‐making and impact assessment in pharmacovigilance
by: Ignatios Ioakeim‐Skoufa, et al.
Published: (2025)

Correction to “Evaluating the impact of general practice pharmacist‐led person‐centred medicines reviews on medicines appropriateness and patient‐reported outcome measures”
Published: (2026)

Setting up mother–infant pair lactation studies with biobanking for research according to regulatory requirements
by: Mats Hansson, et al.
Published: (2025)

Morbimortality consequences of use and misuse of psychoactive medicines in Portugal
by: Ana Carmona Araújo, et al.
Published: (2025)

Assessment of clinical pharmacology and competence during medicine clerkships
by: Nicole C. Cheung, et al.
Published: (2025)

Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
by: Tatsuaki Takeda, et al.
Published: (2025)

MCF classifier: Estimating, standardizing, and stratifying medicine carbon footprints, at scale
by: Haroon Taylor, et al.
Published: (2024)

Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist
by: Sonia Guleria, et al.
Published: (2024)

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research
by: Titiaan E. Post, et al.
Published: (2024)

Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency
by: Valentina Giunchi, et al.
Published: (2025)

A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU
by: Charlotte W. M. Simons, et al.
Published: (2025)

Patient preferences and attitudes regarding the environmental impact of medicines: A discrete choice experiment
by: Milad Sadreghaemy, et al.
Published: (2025)

Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross‐sectional study
by: Amelia Smith, et al.
Published: (2025)

The impact of pretreatment drug resistance on ainuovirine‐based antiviral therapy in HIV‐infected patients: A subgroup analysis from the RACER study
by: Q. Li, et al.
Published: (2025)

Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings
by: Monica Jung, et al.
Published: (2026)

Efficacy, safety and cost‐effectiveness of CAR‐T therapy
by: Emina Karahmet Sher, et al.
Published: (2026)

Spotlight commentary—Insulin therapy: Future directions
by: Ana Deškin, et al.
Published: (2025)

Application of paediatric cetirizine PBPK model to guide precision medicine and understand renal P‐glycoprotein ontogeny
by: Yafen Li, et al.
Published: (2026)

Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit
by: Jana Stojanova, et al.
Published: (2025)

Evolving trends in acid suppression therapy among patients undergoing dual antiplatelet therapy: A Nationwide study in South Korea from 2018 to 2022
by: Yu Jeong Lee, et al.
Published: (2025)

Acute cardiovascular effects associated with the use of prescription medications: A Danish nationwide screening study
by: Saad Hanif Abbasi, et al.
Published: (2025)

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
by: Catharina J. P. Op 't Hoog, et al.
Published: (2025)

Exploring new avenues: Psychedelic‐assisted therapy for young people
by: Ioanna Artemis Vamvakopoulou, et al.
Published: (2026)

Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy
by: Rita Nogueiras‐Álvarez, et al.
Published: (2024)

Academic development of advanced therapies—How to foster their future in the clinic
by: Ana Hidalgo‐Simon, et al.
Published: (2025)

Association between oral anticoagulant therapy and in‐hospital complications and mortality
by: Juliana Lagrave, et al.
Published: (2025)

Consideration of ethnic differences in approvals for anti‐HIV medicines in Japan: Evaluation based on pharmacokinetic studies and post‐marketing data
by: Rumiko Shimazawa, et al.
Published: (2025)

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects
by: James Goodman, et al.
Published: (2025)

Initiation of lipid‐lowering therapy as primary prevention of cardiovascular disease in the elderly
by: José Manuel Vinuesa‐Hernando, et al.
Published: (2024)

Population pharmacokinetics of long‐term hydroxychloroquine therapy in patients with rheumatic diseases
by: Chunlan Yang, et al.
Published: (2024)

Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
by: Dai Lian, et al.
Published: (2024)

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II
by: Kimitoshi Nakamura, et al.
Published: (2026)